Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma
This study will evaluate the safety and efficacy of NK510 in the treatment of Osteosarcoma and Soft Tissue Sarcoma.NK510 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.
Osteosarcoma|Soft Tissue Sarcoma
DRUG: NK510|DRUG: NK510
Dose-Limiting Toxicity, To evaluate the DLT during N510 treatment, 6 weeks|Maximal Tolerable Dose, To evaluate the MTD of NK510, 6 weeks
Overall response rate (ORR), Effectiveness Metrics, 6 weeks
This study will evaluate the safety and efficacy of NK510 in the treatment of Osteosarcoma and Soft Tissue Sarcoma.NK510 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.